<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
    <study_info>
        <title>Statin Therapy in Primary Prevention: A Meta-Analysis Challenging Current Guidelines</title>
        <authors>
            <author>
                <name>Prof. Alexandra Petrov</name>
                <affiliation>Department of Cardiology, University of Copenhagen, Denmark</affiliation>
                <email>apetrov@ku.dk</email>
            </author>
            <author>
                <name>Dr. Roberto Martinez</name>
                <affiliation>Institute of Cardiovascular Medicine, University of Barcelona, Spain</affiliation>
                <email>rmartinez@ub.edu</email>
            </author>
            <author>
                <name>Dr. Yuki Tanaka</name>
                <affiliation>Department of Preventive Cardiology, Tokyo Medical University, Japan</affiliation>
                <email>ytanaka@tmu.ac.jp</email>
            </author>
        </authors>
        <journal>European Heart Journal</journal>
        <publication_date>2024-03-15</publication_date>
        <doi>10.1093/eurheartj/ehae123</doi>
        <study_type>systematic_review_meta_analysis</study_type>
        <evidence_level>very_high</evidence_level>
    </study_info>

    <abstract>
        <background>
            Current guidelines recommend statin therapy for primary prevention in patients with 10-year cardiovascular risk ≥7.5%. However, recent studies suggest this threshold may be too low, leading to overtreatment and unnecessary adverse effects.
        </background>
        <methods>
            We conducted a systematic review and meta-analysis of randomized controlled trials comparing statin therapy to placebo in primary prevention. We searched MEDLINE, Embase, and Cochrane databases through December 2023, including 28 trials with 186,854 participants.
        </methods>
        <results>
            **CONTRADICTORY FINDING:** Statin therapy showed no significant cardiovascular benefit in patients with 10-year risk &lt;15% (RR 0.94, 95% CI: 0.86-1.03, p=0.18). Number needed to treat was 312 for patients with 7.5-15% risk, compared to 67 for patients with &gt;20% risk.
        </results>
        <conclusions>
            These findings challenge current guideline recommendations and suggest raising the threshold for statin initiation in primary prevention from 7.5% to 15% 10-year cardiovascular risk.
        </conclusions>
    </abstract>

    <main_findings>
        <finding id="1">
            <category>Primary Prevention Efficacy</category>
            <description>Statin therapy in patients with 7.5-15% 10-year cardiovascular risk showed no statistically significant reduction in major adverse cardiovascular events (MACE)</description>
            <relative_risk>0.94 (95% CI: 0.86-1.03)</relative_risk>
            <p_value>0.18</p_value>
            <number_needed_to_treat>312</number_needed_to_treat>
            <contradicts_guidelines>true</contradicts_guidelines>
            <guideline_contradicted>AHA/ACC Primary Prevention Guidelines 2019</guideline_contradicted>
        </finding>

        <finding id="2">
            <category>Adverse Effects</category>
            <description>Statin-associated muscle symptoms occurred in 11.2% of patients vs 7.1% with placebo (p&lt;0.001)</description>
            <relative_risk>1.58 (95% CI: 1.42-1.76)</relative_risk>
            <number_needed_to_harm>24</number_needed_to_harm>
            <clinical_significance>high</clinical_significance>
        </finding>

        <finding id="3">
            <category>New-Onset Diabetes</category>
            <description>Statin therapy increased risk of new-onset diabetes by 12% (RR 1.12, 95% CI: 1.06-1.18)</description>
            <relative_risk>1.12 (95% CI: 1.06-1.18)</relative_risk>
            <p_value>0.001</p_value>
            <number_needed_to_harm>167</number_needed_to_harm>
            <note>Risk highest in patients with prediabetes and metabolic syndrome</note>
        </finding>

        <finding id="4">
            <category>Cost-Effectiveness</category>
            <description>Cost per quality-adjusted life year (QALY) exceeded $100,000 for patients with &lt;15% 10-year risk</description>
            <cost_per_qaly_low_risk>$127,000</cost_per_qaly_low_risk>
            <cost_per_qaly_high_risk>$23,000</cost_per_qaly_high_risk>
            <cost_effective_threshold>$50,000</cost_effective_threshold>
        </finding>
    </main_findings>

    <methodology>
        <search_strategy>
            <databases>MEDLINE, Embase, Cochrane Central Register of Controlled Trials</databases>
            <search_period>January 1990 to December 2023</search_period>
            <search_terms>statin, primary prevention, cardiovascular disease, randomized controlled trial</search_terms>
        </search_strategy>

        <inclusion_criteria>
            <criterion>Randomized controlled trials</criterion>
            <criterion>Primary prevention population (no known cardiovascular disease)</criterion>
            <criterion>Statin vs placebo comparison</criterion>
            <criterion>Follow-up ≥2 years</criterion>
            <criterion>Cardiovascular outcomes reported</criterion>
        </inclusion_criteria>

        <exclusion_criteria>
            <criterion>Secondary prevention studies</criterion>
            <criterion>Statin vs statin comparisons</criterion>
            <criterion>Follow-up &lt;2 years</criterion>
            <criterion>Insufficient outcome data</criterion>
        </exclusion_criteria>

        <primary_outcomes>
            <outcome>Major adverse cardiovascular events (MACE): composite of cardiovascular death, non-fatal MI, non-fatal stroke</outcome>
        </primary_outcomes>

        <secondary_outcomes>
            <outcome>All-cause mortality</outcome>
            <outcome>Cardiovascular mortality</outcome>
            <outcome>Non-fatal myocardial infarction</outcome>
            <outcome>Non-fatal stroke</outcome>
            <outcome>Coronary revascularization</outcome>
            <outcome>Adverse events</outcome>
        </secondary_outcomes>
    </methodology>

    <results_by_risk_group>
        <risk_group name="Low risk (&lt;7.5%)">
            <participants>34,567</participants>
            <mace_events_statin>234</mace_events_statin>
            <mace_events_placebo>267</mace_events_placebo>
            <relative_risk>0.88 (95% CI: 0.74-1.04)</relative_risk>
            <p_value>0.13</p_value>
            <nnt>456</nnt>
            <conclusion>No significant benefit</conclusion>
        </risk_group>

        <risk_group name="Intermediate risk (7.5-15%)">
            <participants>89,234</participants>
            <mace_events_statin>1,234</mace_events_statin>
            <mace_events_placebo>1,312</mace_events_placebo>
            <relative_risk>0.94 (95% CI: 0.86-1.03)</relative_risk>
            <p_value>0.18</p_value>
            <nnt>312</nnt>
            <conclusion>No significant benefit - CONTRADICTS GUIDELINES</conclusion>
        </risk_group>

        <risk_group name="High risk (15-20%)">
            <participants>45,123</participants>
            <mace_events_statin>1,567</mace_events_statin>
            <mace_events_placebo>1,834</mace_events_placebo>
            <relative_risk>0.85 (95% CI: 0.79-0.92)</relative_risk>
            <p_value>&lt;0.001</p_value>
            <nnt>89</nnt>
            <conclusion>Significant benefit</conclusion>
        </risk_group>

        <risk_group name="Very high risk (&gt;20%)">
            <participants>17,930</participants>
            <mace_events_statin>1,234</mace_events_statin>
            <mace_events_placebo>1,567</mace_events_placebo>
            <relative_risk>0.79 (95% CI: 0.72-0.86)</relative_risk>
            <p_value>&lt;0.001</p_value>
            <nnt>67</nnt>
            <conclusion>Strong benefit</conclusion>
        </risk_group>
    </results_by_risk_group>

    <adverse_events>
        <muscle_symptoms>
            <statin_group>10,456 (11.2%)</statin_group>
            <placebo_group>6,634 (7.1%)</placebo_group>
            <relative_risk>1.58 (95% CI: 1.42-1.76)</relative_risk>
            <nnh>24</nnh>
        </muscle_symptoms>

        <liver_enzyme_elevation>
            <statin_group>1,234 (1.3%)</statin_group>
            <placebo_group>456 (0.5%)</placebo_group>
            <relative_risk>2.71 (95% CI: 2.12-3.47)</relative_risk>
            <nnh>125</nnh>
        </liver_enzyme_elevation>

        <new_onset_diabetes>
            <statin_group>3,456 (3.7%)</statin_group>
            <placebo_group>3,089 (3.3%)</placebo_group>
            <relative_risk>1.12 (95% CI: 1.06-1.18)</relative_risk>
            <nnh>167</nnh>
        </new_onset_diabetes>
    </adverse_events>

    <discussion>
        <key_points>
            <point>
                <title>Guideline Threshold Questioned</title>
                <content>**MAJOR CONTRADICTION:** Our meta-analysis demonstrates no significant cardiovascular benefit from statin therapy in patients with 7.5-15% 10-year cardiovascular risk, directly contradicting AHA/ACC guidelines that recommend statin therapy at ≥7.5% risk threshold.</content>
            </point>
            <point>
                <title>Risk-Benefit Balance</title>
                <content>The number needed to treat of 312 in intermediate-risk patients, combined with a number needed to harm of 24 for muscle symptoms, suggests an unfavorable risk-benefit profile for this population.</content>
            </point>
            <point>
                <title>Cost-Effectiveness Concerns</title>
                <content>Cost per QALY exceeding $100,000 in low-intermediate risk patients raises questions about resource allocation and healthcare economics of current statin prescribing practices.</content>
            </point>
        </key_points>

        <clinical_implications>
            <implication>
                <recommendation>Consider raising statin initiation threshold from 7.5% to 15% 10-year cardiovascular risk</recommendation>
                <strength>Strong</strength>
                <evidence_level>Very High</evidence_level>
            </implication>
            <implication>
                <recommendation>Enhanced shared decision-making for patients with 7.5-15% risk, emphasizing lifestyle interventions</recommendation>
                <strength>Strong</strength>
                <evidence_level>High</evidence_level>
            </implication>
        </clinical_implications>
    </discussion>

    <conclusions>
        <primary_conclusion>
            Statin therapy for primary prevention shows no significant cardiovascular benefit in patients with 10-year risk &lt;15%, challenging current guideline recommendations and suggesting a need for higher treatment thresholds.
        </primary_conclusion>
        <clinical_impact>
            These findings could prevent overtreatment of millions of patients worldwide and redirect focus toward lifestyle interventions and more targeted pharmacotherapy.
        </clinical_impact>
    </conclusions>

    <funding>
        <source>European Research Council</source>
        <grant_number>ERC-2021-ADG-101054321</grant_number>
    </funding>

    <conflicts_of_interest>
        <author name="Prof. Alexandra Petrov">None declared</author>
        <author name="Dr. Roberto Martinez">None declared</author>
        <author name="Dr. Yuki Tanaka">Research grants from Japanese Heart Foundation</author>
    </conflicts_of_interest>
</clinical_study>